Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin

Metabolism: Clinical and Experimental

Volumn 57, Issue 3, 2008, Pages 321-325

  Siepi, Donatella ^a   Marchesi, Simona ^a   Vaudo, Gaetano ^a   Lupattelli, Graziana ^a   Bagaglia, Francesco ^a   Pirro, Matteo ^a   Brozzetti, Matteo ^a   Roscini, Anna Rita ^a   Mannarino, Elmo ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ABDOMINAL FAT; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; ADULT; AGED; AGING; ANTHROPOMETRY; ARTERIES; ATHEROSCLEROSIS; BONE REMODELING; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CAROTID ARTERIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; VASCULAR DISEASES; VASODILATION;

EID: 38749092671     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.10.005     Document Type: Article

References (26)

1. Dovio A., Data V., and Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?. J Endocrinol Invest 28 (2005) 14-22
2. Anand D.V., Lahiri A., Lim E., Hopkins D., and Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47 (2006) 1850-1857
3. Vik A., Mathiesen E.B., Noto A.T., Sveinbjornsson B., Brox J., and Hansen J.B. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 191 (2007) 128-134
4. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
5. Rhee E.J., Lee W.Y., Kim S.Y., Kim B.J., Sung K.C., Kim B.S., et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 108 (2005) 237-243
6. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44 (2004) 1970-1976
7. Mitka M. Obesity's role in heart disease requires apples and pears comparison. JAMA 294 (2005) 3071-3072
8. Stevens J., Cai J., Pamuk E.R., Williamson D.F., Thun M.J., and Wood J.L. The effect of age on the association between body mass index and mortality. N Engl J Med 338 (1998) 1-7
9. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 160 (2000) 898-904
10. Ronti T., Lupattelli G., and Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 64 (2006) 355-365
11. Douchi T, Kosha S, Uto H, Oki T, Nakae M, Yoshimitsu N. et al. Precedence of bone loss over changes in body composition and body fat distribution within a few years after menopause. Maturitas 2003;46:133-864, 355-65.
12. Marchesi S., Lupattelli G., Schillaci G., Pirro M., Siepi D., Roscini A.R., et al. Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men. Atherosclerosis 153 (2000) 397-402
13. Vaudo G., Schillaci G., Evangelista F., Pasqualini L., Verdecchia P., and Mannarino E. Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential hypertension. Am J Hypertens 13 (2000) 324-331
14. Douchi T., Kosha S., Uto H., Oki T., Nakae M., Yoshimitsu N., et al. Precedence of bone loss over changes in body composition and body fat distribution within a few years after menopause. Maturitas 46 (2003) 133-138
15. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23 (2006) 469-480
16. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
17. Hofbauer L.C., and Schoppet M. Serum measurement of osteoprotegerin-clinical relevance and potential applications. Eur J Endocrinol 145 (2001) 681-683
18. Sattler A.M., Schoppet M., Schaefer J.R., and Hofbauer L.C. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 74 (2004) 103-106
19. Rutsch F., and Terkeltaub R. Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. Curr Opin Rheumatol 15 (2003) 302-310
20. Sandberg W.J., Yndestad A., Oie E., Smith C., Ueland T., Ovchinnikova O., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26 (2006) 857-863
21. Ueland T., Yndestad A., Oie E., Florholmen G., Halvorsen B., Froland S.S., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111 (2005) 2461-2468
22. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 (2001) 1610-1616
23. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clark E.A., and Giachelli C.M. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275 (2000) 20959-20962
24. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
25. Kim S.M., Lee J., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf) 63 (2005) 594-598
26. Gannage-Yared M.H., Fares F., Semaan M., Khalife S., and Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 64 (2006) 652-658